IBio, Inc. Appoints Robert M. Lutz as Chief Financial & Business Officer, Effective March 4, 2021
February 16, 2021 at 01:00 pm
Share
iBio, Inc. announced the appointment of Robert M. Lutz as its Chief Financial & Business Officer (“CFBO”), effective March 4, 2021. Mr. Lutz brings more than 25 years of experience to the Company, joining most recently from Strongbridge Biopharma plc. He served as CFO since August 2019, and prior to that, as Chief Business Officer since October 2014. As CFBO, Mr. Lutz will lead iBio’s finance organization and be responsible for building strong licensing capabilities and the financial planning & analysis function, as well as supporting iBio’s relationships with the investment community.
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.